Medincell Stock Drops Over 3% as Annual Results Approach
The biotech company from Montpellier experiences a sharp decline mid-session, going against its recent momentum. The stock struggles at the bottom of the SBF 120 while the Parisian market itself moves into negative territory. This movement occurs just days before a highly anticipated accounting event.
The stock downgrades below its 20-day moving average and ranks among the steepest declines of the SBF 120
Medincell stock drops 3.24% to €26.90 during the session, down from €27.80 the previous day. The stock is among the sharpest declines in the SBF 120, which itself has fallen by 0.35%. This downturn breaks the momentum that began last week when the stock had risen nearly 3% on Monday according to a previous report. The price has fallen below its 20-day moving average (€27.23), with a gap of 1.21% below this short-term benchmark. However, the backdrop remains favorable over the long term: the performance is up +23.3% over three months and +68.1% over a year. The RSI at 57 remains neutral, showing no signs of exhaustion.
A technical retreat before the announcement of annual results on June 16
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's decline occurs just a few sessions before the announcement of the annual accounts (fiscal year April 2025-March 2026), scheduled for June 16. This event will be an opportunity for the biotech to detail the progress of its partnerships, notably the one with Teva on extended-release olanzapine, whose file was accepted by the EMA on May 22. Despite today's drop, the stock maintains a significant cushion over its long-term benchmarks: it is 6.03% above its MM50 (€25.37) and 5.16% above its MM200 (€25.58). The medium-term structure remains bullish, even though the price has moved away from the resistance of €28.72 reached at the end of May. The annual publication, expected on June 16, will deliver the figures and roadmap for the new fiscal year.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Contexte
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
Les informations présentées dans cet article sont fournies à titre purement indicatif et ne constituent en aucun cas une recommandation d'investissement, une incitation à acheter ou vendre un actif financier, ni un conseil en placement. Le lecteur est invité à réaliser ses propres recherches avant toute décision.
Les investissements en bourse comportent des risques, notamment de perte en capital. La performance passée d'un actif ou d'un marché ne présage en rien de ses performances futures. Toute décision d'investissement doit être prise en tenant compte de votre situation financière personnelle, de vos objectifs et de votre tolérance au risque.
